Posts Tagged ‘pharmaceuticals’

  • Conflicts of interest reported for FDA panel that signed off on Yaz birth control drug Wednesday, January 11, 2012 � by jg

    Washington Monthly blog: An investigation by journalists found some members of a U.S. Food and Drug Administration committee of medical experts that looked into the potential dangers of the Bayer birth control pills Yaz and Yasmin had potential conflicts of interest.

  • FDA advisers recommend stronger warnings for Yaz, Yasmin birth control pills Friday, December 9, 2011 � by jg

    Washington Post: Members of two U.S. Food and Drug Administration committees voted that the labels now on the pills don’t provide adequate warning about the pills’ potential for causing blood clots.

  • Former FDA head says Bayer withheld data about Yasmin Monday, December 5, 2011 � by jg

    Bloomberg: David Kessler says in court documents that the pharmaceutical giant withheld information that users of the company’s Yasmin birth control pills had increased reports of blood clots.

  • Yaz contraceptive continues to generate lawsuits Monday, July 11, 2011 � by jg

    Newark (N.J.) Star-Ledger: Bayer Healthcare allegedly did not provide adequate warnings about the health risks associated with the oral contraceptive, which has been lamed for causing blood clots, heart attacks and strokes.

  • Drugmaker agrees to pay more than $1 billion in Paxil settlements Wednesday, July 28, 2010 � by jg

    Bloomberg BusinessWeek: GlaxoSmithKline’s latest agreement involves more than 800 birth defect cases and brings the total it has agreed to pay in Paxil-related settlements to more than $2 billion.

  • Jury awards $8 million in Fosamax case Monday, June 28, 2010 � by jg

    Associated Press: A 72-year-old woman has been awarded $8 million in compensatory damages after a jury ruled Fosamax is “unreasonably dangerous due to defective design.”

  • A (small) victory for medical patients, and ethics Thursday, June 24, 2010 � by scott

    The University of Michigan Medical School has decided that it will no longer accept cash from drug companies to underwrite courses designed to keep doctors’ medical licenses current.